Programmed death ligand 1 (PD-L1) expression on myeloma cells is induced by JAK2, STAT3, and MEK1/2-mediated interleukin-6 signaling, a strong inducer of PD-L1 interferon-γ produced by T and natural killer cells, and APRIL produced by osteoclasts in the tumor microenvironment. The soluble form of PD-L1, derived from extracellular domains of PD-L1 molecules expressed in the tumor environment, may also contribute to tumor immune evasion. PD-L1-expressing myeloma cells not only have the ability to escape from the attack of tumor-specific T cells but also high proliferation potential. Furthermore, PD-L1 on myeloma cells delivers a reverse signal to tumor cells through PD-1 binding, resulting in the phosphorylation of Akt accompanied by the acquisition of resistance to anti-myeloma agents. Based on the function of PD-L1 in myeloma, the blockade of the PD-1-PD-L1 pathway is a reasonable treatment in refractory patients. Phase I/II clinical trials of anti-PD-1 antibody combined with immunomodulatory drugs demonstrated excellent effects in heavily pretreated multiple myeloma patients with acceptable tolerability. The timing and combination drug of anti-PD-1/PD-L1 antibodies should be considered to improve clinical effects with low mortality in refractory myeloma patients.
Introduction
Prognosis in patients with multiple myeloma (MM) has improved markedly, although it remains incurable. New treatment strategies including immunotherapies such as immune checkpoint inhibitors and chimeric antigen receptor-T cell (CART) therapy are expected to improve survival rates, and many clinical trials of immunotherapies for MM have been reported and are ongoing 1, 2 . For the development of more efficient immunotherapies, it is crucial to elucidate the mechanism of immunosuppression in MM. Programmed death ligand 1 (PD-L1), first identified as a B7 homologue 1 (B7-H1) in humans and mice 3, 4 , is expressed on most tumor cells and can induce the apoptosis of tumorspecific T cells, resulting in tumor immune evasion 5 . Immunotherapies targeting the blockade of the PD-1−PD-L1 pathway, which can induce tumor-specific cytotoxic T lymphocytes (CTLs), have shown clinical efficacy in many types of cancer. In hematological malignancies, anti-PD-1 antibodies have been approved for patients with Hodgkin lymphoma, in which high levels of PD-L1 expression on tumor cells occur 6 . This paper reviews the expression and functions of PD-L1 in MM and potential treatment with its inhibitors for refractory MM patients. levels in tumors are regulated in a highly complex manner, with genomic aberrations, transcriptional control, mRNA stability, oncogenic signaling, and protein stability 7 . Kataoka et al. reported a unique genetic mechanism of immune escape caused by structural variations commonly disrupting the 3' region of thePD-L1gene, leading to a marked elevation ofaberrantPD-L1transcripts, in a small subset of patients with hematologic malignancies including adult T-cell leukemia/ lymphoma 8 . Plasma cells from MM patients express higher levels of PD-L1 compared with those from healthy volunteers and patients with monoclonal gammopathy of undetermined significance (MGUS) 9, 10 . PD-L1 expression on MM cells is induced by JAK2, STAT3, and MEK1/2-mediated interleukin (IL)-6 signaling 10 , and a strong inducer of PD-L1 interferon (IFN)-γ may be produced by CTLs and natural killer (NK) cells in the tumor microenvironment 11 ( Figure 1 ). Furthermore, high levels of APRIL produced by osteoclasts increase PD-L1 expression on myeloma cells in patients 12 . Some patients with minimal residual disease (MRD) after treatment had higher levels of PD-L1 expression on MM cells compared with the levels before treatment 13 , suggesting that MRD escapes immune surveillance via PD-L1 expression. In the MM microenvironment, immune cells such as myeloid and plasmacytoid dendritic cells (DCs) express higher levels of PD-L1 compared with cells from healthy donors 14 . In MM patients, myeloid-derived suppressor cells (MDSCs), which are a CD11b
myeloid cell population with the ability to suppress innate and adaptive immune responses, are increased in the bone marrow, and some patients were found to have high levels of PD-L1 expressed on MDSCs 15, 16 . The expression of the PD-L1 receptor PD-1 was detected on NK cells freshly isolated from MM patients but not on those from healthy volunteers 17 . In addition, PD-1 expression on CD4 + and CD8 + T cells was significantly increased in bone marrow samples obtained from MRD-positive and refractory MM patients 13 , and those T cells might be depleted after the interaction with PD-L1. In MM patients, PD-L1 induced in the tumor microenvironment may efficiently induce apoptosis of effector cells for tumor cells, i.e., CTLs and NK cells.
PD-L1 Functions in Myeloma Cells
PD-L1-expressing MM cells not only have the ability to escape from attack by tumor-specific CTLs but also high proliferation rates and anti-myeloma drug resistance 10 . PD-L1 + MM cells express higher levels of Ki-67 and BCL2 compared with PD-L1 -MM cells. Consistent with those findings, PD-L1-knockdown MM cells had lower proliferation rates and greater percentages of apoptotic cells induced by anti-myeloma agents such as melphalan and bortezomib 18 . We found that PD-L1 on MM cells delivers a reverse signal to tumor cells through PD-1 binding, resulting in phosphorylation of Akt accompanied by the acquisition of drug resistance 18 ( Figure 1 ), while PD-L1 was reported to deliver anti-apoptotic signals in a mouse tumor model 19 . Our experiments showed that PD-1 
Soluble Form of PD-L1 in Multiple Myeloma
The soluble form of PD-L1 (sPD-L1), which is derived from the extracellular domains of PD-L1 molecules expressed on tumor cells, has a molecular weight of 45 kDa and an Ig-V ligand-binding domain that can bind to PD-1 21 ( Figure 1 ). In vitro analysis showed that sPD-L1 could induce the apoptosis of T cells 22 . In B-cell lymphoma, patients with higher sPD-L1 levels had shorter survival times compared with those with lower levels 23 . We reported that serum sPD-L1 levels in MM patients were significantly higher than those in healthy volunteers, and high levels of serum sB7-H1 were associated with symptomatic MM 24 . Furthermore, MM patients with high levels of serum sPD-L1 were found to have a poorer prognosis in terms of progression-free survival and overall survival 25 . However, the mechanism by which the soluble form is shed from the surface of PD-L1 on tumor cells remains unresolved.
Treatment Potential of Anti-PD-1/PD-L1 Antibodies
Based on the crucial roles of PD-L1 in MM, anti-PD-1 antibody treatment was expected to demonstrate efficacy in MM patients. However, the anti-PD-1 antibody nivolumab alone showed poor clinical results, with stable disease in 63% of patients 1 ; only one of 27 MM patients who responded to nivolumab and achieved stable disease but then experienced disease progression with plasmacytoma achieved a complete response (CR) after radiation therapy for a plasmacytoma of the rib. This suggests that the combination of anti-PD-1 antibody immunotherapy with radiation might be effective in MM, similar to the results in other tumors. The reason for the lack of response to the immune checkpoint inhibitor might be due to the immunosuppression of T cells because advanced MM patients have various immune deficiencies including insufficient expansion of tumor-specific CTLs 26 . However, combined immunotherapy with anti-PD-1 antibody plus immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide was reported to have surprising effects in heavily pretreated patients. The anti-PD-1 antibody pembrolizumab combined with pomalidomide and dexamethasone was administered to refractory MM patients aged 35-83 (median 64) years who had received 2-5 (median 3) prior regimens, including double-refractory patients (73%) and patients with high-risk abnormal cytogenetics (73%). That phase II clinical trial demonstrated a 60% overall response rate including a stringent CR/CR rate of 8%, very good partial response rate of 19%, and partial response rate of 33%, with a median response duration of 14.7 months 27 . The treatment strategy combining IMiDs with anti-PD-1 antibody was thought to have sufficient clinical efficacy for heavily pretreated MM patients with acceptable tolerability. However, the combination regimen showed an increased mortality rate as detected in the interim analyses of phase III randomized studies, the KEYNOTE-183 (pembrolizumab plus pomalidomide and dexamethasone for relapsed/refractory MM)and -185 trials (pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed MM), although the increase did not reach statistical significance 28 . The cause of death included cardiac events, which might involve the overactivation of T cells as seen in PD-1-deficient BALB/c mice that developed autoimmune dilated cardiomyopathy 29 . The response rate was lower in patients who experienced no immune-related adverse events, suggesting that an excess immune response may be associated with high mortality rates. There are no data on anti-PD-L1 antibody treatment in MM, although it might be promising because PD-L1 is expressed not only on MM cells but also on tumor-associated accessory cells in the tumor microenvironment and functions in tumor cells. As further directions, the timing of administration and combination of anti-PD-1/PD-L1 antibodies with other drugs should be considered carefully to improve the clinical outcomes of PD-1-PD-L1 pathway blockade in MM patients. Furthermore, to predict the response and occurrence of adverse events, useful markers, for example, levels of PD-L1 expression on MM cells and soluble PD-L1, should be incorporated in future clinical studies using anti-PD-L1/PD-1 antibodies.
Conclusion
In the MM tumor microenvironment, PD-L1 is inducibly expressed not only on MM cells but also on immune cells including DCs and MDSCs and inhibits the anti-tumor immunity of T cells. The soluble form of PD-L1 released from tumor cells may induce T-cell apoptosis. Furthermore, PD-L1 on MM cells binding PD-1 can deliver anti-apoptotic signals through the PI3K/Akt signaling pathway, which may be associated with disease progression. The blockade of PD-1 on MM cells increases apoptosis induced by anti-myeloma agents, suggesting the potential of anti-PD-1/PD-L1 antibody treatment combined with chemotherapy. In the future, it will be necessary to assess the timing of the administration of immune checkpoint inhibitors and their combination with other treatment modalities, i.e., radiation, chemotherapy, and T-cell immunotherapies such as DC tumor vaccine and CART therapy.
